Transaction Details
- Acquiring Entity: Aurobindo Pharma USA Inc. (APUSA), wholly owned subsidiary of Aurobindo Pharma Limited
- Acquired Entity: Lannett Company, Inc., USA ("Lannett")
- Seller: Lannett Seller Holdco, Inc.
- Regulatory Approval: Received approval from U.S. Federal Trade Commission on June 18, 2026
- Completion Date: Transaction completed effective June 29, 2026
- Previous Communications: Referenced letter dated June 19, 2026 and press release dated June 22, 2026
Post-Acquisition Structure
Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC.
Integration Plans
Integration process commences immediately with focus on:
- Ensuring uninterrupted access to critical medications
- Maintaining trusted relationships with partners
- Supporting employees throughout the transition
- Combining capabilities and resources to enhance availability of essential medicines
- Delivering sustained, long-term value to patients, customers, and stakeholders
Workforce Impact
APUSA welcomes more than 400 Lannett employees to its organization, strengthening talent base and operational capabilities.
Acknowledgments
Management expresses appreciation to Lannett's management team for their leadership in enabling a smooth transition and valuable contributions to the organization.